Fierce Biotech4d
Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Clinical Trials Arena on MSN4d
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Seeking Alpha29d
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...
pharmaphorum7d
Novo Nordisk sheds billions in value on obesity data
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
Morningstar18d
Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug – Hagens Berman
Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...